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Membrane skeletal protein 4.1R is the prototypical member of a family of four highly paralogous proteins that include 4.1G, 4.1N,
a n d4 . 1 B .T w oi s o f o rm so f4 . 1 R( 4 . 1 R 135 and 4.1R80), as well as 4.1G, are expressed in erythroblasts during terminal diﬀerentiation,
but only 4.1R80 is present in mature erythrocytes. One goal in the ﬁeld is to better understand the complex regulation of cell
type and isoform-speciﬁc expression of 4.1 proteins. To start answering these questions, we are studying in depth the important
functions of 4.1 proteins in the organization and function of the membrane skeleton in erythrocytes. We have previously reported
thatthebindingproﬁlesof4.1R80 and4.1R135 tomembraneproteinsandcalmodulinareverydiﬀerentdespitethesimilarstructure
of the membrane-binding domain of 4.1G and 4.1R135. We have accumulated evidence for those diﬀerences being caused by the
N-terminal 209 amino acids headpiece region (HP). Interestingly, the HP region is an unstructured domain. Here we present
an overview of the diﬀerences and similarities between 4.1 isoforms and paralogs. We also discuss the biological signiﬁcance of
unstructured domains.
1. 4.1R inthe ErythrocyteMembrane Skeleton
The membrane skeleton, which underlies the erythro-
cyte plasma membrane, is made of a spectrin/actin lat-
tice anchored to various transmembrane proteins via two
specialized cytoskeletal proteins, 4.1R and red blood cell
ankyrin, ankyrin-R [1]. 4.1R80 stabilizes horizontal inter-
actions between spectrin heterodimers (α2-β2) and short
actin (∼14 molecules) ﬁlaments. Actin ﬁlaments interact
with numerous accessory proteins, such as tropomyosin,
myosin, tropomodulin, and adducin [1], which ensure reor-
ganization of actin ﬁlaments. 4.1R80 interacts also with the
transmembrane protein, glycophorin C (GPC) and with the
membrane-associated guanylate kinase (MAGUK) protein
p55, which also acts as an erythrocyte scaﬀolding protein
(Figure 1).
1.1. GPC. GPC is 32kDa single transmembrane protein
expressed at ∼50,000−100,000 molecules/erythrocyte. The
cytoplasmic domain consists of 47 amino acids residues (ID:
P04921).TheR82HKsequencehasbeenidentiﬁedasthe4.1R
binding sequence [2–4]. This RHK motif is highly conserved
in the cytoplasmic domain of Neurexin IV, Paranodin, and
T S L C 1( T u m o rS u p p r e s s o rL u n gC a n c e r1 )[ 5]. Girault et
al. have designated this RHK motif “GNP-motif,” after the
singletransmembrane4.1Rbindingproteins,GPC,Neurexin
IV, Paranodin [6]. GPC and other GNP-motif containing
proteins possess a p55 binding motif, EYFI, in their C-
terminal region (Figure 2).
1.2. p55. p55 is a 55kDa erythrocyte scaﬀolding protein
that belongs to the membrane-associated guanylate kinase
homologues (MAGUK) family (ID: Q00013). This protein
is characterized by the presence of a PDZ (Postsynaptic
density protein-95, Dlg (Drosophila disc large tumor sup-
pressor), ZO-1 (Zonula Occludens-1)) domain, an SH (src-
homology) 3 domain, and a catalytic inactive guanylate
kinase like (GUK) domain, all of which function as protein-
protein interaction modules (Figure 2)[ 8]. The number of
p55 copies in the human erythrocytes is ∼80,000. p55 is
also called Membrane Palmitoylated Protein 1 (MPP1) since2 International Journal of Cell Biology
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Figure 1: Structure of human erythrocyte membrane. Spectrin dimers underlying the membrane interact with transmembrane proteins
band3throughankyrinandglycophorinC(GPC)throughanactincomplexandprotein4.1R80(4.1R80).4.1R80 alsoformsaternarycomplex
with p55 and GPC. CaM binds to 4.1R80 in a Ca2+-independent manner.
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Figure 2: Organization of the R30/GPC/p55 ternary complex. The NMR structure of GPC peptide and PDZ domain complex has been
previously reported [7] (PDB accession no. 2ejy). The HOOK domain is the 4.1R binding site for p55 [4].International Journal of Cell Biology 3
Band 3
Y
R
L
R
R
a b
Lipid bilayer
N-lobe
α-lobe
R30
L E
E
D
Y
C-lobe
Figure 3: Characteristics of 4.1R interaction with band 3. Band 3 forms dimers in the membrane (a and b). The LRRRY sequence mediates
interaction between monomers and is located in an α-helix. The band 3 binding sequence LEEDY, which mediates interaction with 4.1R, is
located in the loop structure [15] (PDB accession no. 1hyn). There is no information about the stoichiometry of band 3 binding to 4.1R.
cysteine residues in the GUK domain can be palmitoylated
[8]. However, there is still no direct evidence for the
expression of palmitoylated p55 in living cells. Although the
function of p55 in erythrocytes has not been clariﬁed, p55
seems essential for maintenance of polarity in neutrophils
[9] and in hair cells [10, 11]. Recently, NMR-based studies
have enabled to characterize the 3D structural proﬁle of
the GPC peptide that interacts with the PDZ domain of
p55 [7]. Mutational studies, based on the replacement of
the phenylalanine residue in the EYFI motif with a cysteine
residue (E125YCI), have provided us with structural informa-
tion on GPC binding to p55. Thus, 4.1R80 participates in the
formationoftwodiﬀerentternarycomplexesinerythrocytes,
the 4.1R80/GPC/p55/ complex and the 4.1R80/spectrin/actin
complex.Ektacytometrystudieshaverevealedthat4.1Rplays
a key role in controlling erythrocyte membrane mechani-
cal properties. Indeed, resealed membranes prepared from
erythrocytes totally or partially deﬁcient in 4.1R80 show a
dramatic decrease in membrane stability (reviewed in [12]).
Interestingly, addition of either puriﬁed 4.1R80 or puriﬁed
10kDa spectrin-actin binding domain of 4.1R80 to unstable
4.1R-deﬁcient membranes is able to restore mechanical sta-
bility to such membranes. This demonstrates unequivocally
an essential role for 4.1R80 and more speciﬁcally for a 21-
a m i n o - a c i dp e p t i d ee n c o d e db ye x o n1 6i nt h es p e c t r i n -
actin binding domain, in maintaining membrane stability by
promoting spectrin/actin interactions [1, 12].
1.3. Band 3. Membrane stability is also controlled in part by
band 3-ankyrin-spectrin interaction (as shown in Figure 1).
Band 3 is a 102kDa 14-transmembrane protein which
mediates exchange of HCO3
− and Cl− and is therefore
referred to as anion exchanger 1 (AE1) [1] (ID: P02730).
It is expressed at 1,200,000 molecules/cell. It forms dimers
that assemble into tetramers, each tetramer binding to one
molecule of ankyrin. This is the base for the organization of
the band 3-ankyrin-spectrin complex [13].
4.1R binds to the I386RRRY and L343RRRY sequences
in band 3-cytoplasmic domain [14]. Although the crystal
structure of the N-terminal cytoplasmic domain of band
3 has been reported, this structure is putative as the N-
terminal 55 residues, including the L343RRRY sequence, were
missing in the crystal [15]. The results indicate that band
3 has four 4.1R binding sites. The stoichiometry of band
3 binding to 4.1R is still unknown. The importance of
band 3 in membrane architecture results from its role in
anchoring the spectrin network through interaction with the
scaﬀold protein ankyrin. We have demonstrated that 4.1R80
modulates band 3 interaction with ankyrin [16]. We have
characterized a similar function for 4.1R80 in modulating
ankyrin interaction with CD44, a single transmembrane
protein which acts as receptor for hyaluronic acid [17].
The absence of 4.1R, ankyrin, or spectrin or selected
mutations in these proteins result in alterations in erythro-
cyte shape and mechanical properties (reviewed in [1, 12]).
We have demonstrated that 4.1R interacts with membrane
p r o t e i na n a l o g u e si nz e b r a ﬁ s h( Danio rerio) using in vitro
binding assays [18, 19]( I D :N P778259). Salomao et al.
have documented that protein 4.1R80 can bind in vitro to
additionalerythrocytetransmembraneproteins,suchasKell,
XK, Rh, and Duﬀy[ 20]. These interactions remain to be
validated in vivo. The function of 4.1R has been inferred
from the hematopoietic phenotype observed in human 4.1R-
deﬁcient patients, in transgenic 4.1R knock-out mice, and4 International Journal of Cell Biology
in zebraﬁsh (Danio rerio) subjected to chemical mutagenesis
[21]. 4.1R deﬁciency leads to hereditary elliptocytosis (HE),
erythrocytes losing their typical biconcave disc shape to
become elliptical. Thus, 4.1R acts in concert with other
membrane proteins for maintaining normal erythrocyte
shape [22].
2. PART I: 4.1R80 and4.1R135 inErythropoiesis
2.1. Overview of 4.1R Structure. 4.1R forms multimolecular
complexes with transmembrane proteins and membrane-
associated proteins, such as spectrin and actin [1]. Such
complexes, which are critical for maintaining structural
stability in red blood cells, could well be involved in other
functions in nonerythroid cells, such as, for example, signal
transduction at sites of cell-cell and/or cell-matrix contacts.
4.1R80 (ID: P11171), present at approximately 200,000
copies per erythrocyte, can be extracted by high salt
treatment of inside-out vesicles (IOVs), which correspond
to erythrocytes membranes depleted of spectrin and actin.
Based on its 622-amino-acid composition (reviewed in [1,
12]),thepredictedmolecularweightof4.1Risonly ∼70kDa,
thediscrepancywiththeapparentmolecularweightresulting
in part from the unstructured domains of 4.1R. Limited α-
chymotryptic digestion of 4.1R generates four polypeptides:
a 30kDa N-terminal membrane-binding domain, a 16kDa
domain, a 10kDa spectrin-actin binding domain, and a
22/24kDa C-terminal domain (reviewed in [1, 12]). A
4.1R isoform expressed in erythroblasts, but not in mature
erythrocytes, contains an extra N-terminal 209 amino acids
headpiece (HP) region. The apparent molecular weight of
this 4.1R isoform in SDS-PAGE is ∼135kDa, and it is
therefore referred to as 4.1R135. However, its theoretical
molecular weight is ∼100kDa. This discrepancy results from
the unstructured state of the HP region [23].
2.2. Unstructured N-Terminal and Structured 30kDa FERM
Domains of 4.1R135. We calculated the disorder probability
of the N-terminal HP region and the FERM domain using
the PrDOS software (http://prdos.hgc.jp/cgi-bin/top.cgi)
[26]. A value greater than 0.5 reﬂects a disordered structure,
with a probability of false prediction of 5% or less. Our anal-
ysis indicates a highly disordered structure for the HP region
(amino acids 1–209) that contrasts with a highly ordered
structure for the 30kDa FERM domain (amino acids 210–
507). Of particular note, while the overall 209aa HP region
adopts a disordered structure, a short polypeptide (amino
acids 70–80), corresponding to a previously identiﬁed Ca2+-
dependent CaM-binding site [27, 28], does not (Figure 4).
We experimentally demonstrated that the HP is an
unfolded region by SDS-PAGE, size exclusion chromatog-
raphy (SEC), and dynamic light scattering (DLS). The
theoretical molecular weight of 4.1R HP (RHP) is 23kDa
but we estimate its apparent molecular weight as 55kDa by
SDS-PAGE[29].Furthermore,SECanalysisrevealsthatRHP
is eluted between IgG (150kDa) and albumin (68kDa) on
a Sephacryl S-300 column. While the theoretical molecular
weights of the proteins corresponding to amino acids 1–
507 of 4.1R135 (RHP-R30) and to R30 (30kDa FERM
domain) are 56kDa and 32kDa, respectively, they migrate
as polypeptides of >100kDa and 35kDa, respectively, on
SDS-PAGE [29]. By DLS measurements, the hydrodynamic
diameters of RHP, RHP-R30 and R30 are 7.6, 9.4, 5.6nm,
respectively (Nunomura, W., Shiba, K. and Takakuwa, Y.,
unpublished data). These hydrodynamic parameters enabled
us to estimate the molecular weight of RHP, RHP-R30 and
R30tobe77,127,and40kDa,respectively.Thediscrepancies
between theoretical and apparent molecular weights for
proteins containing RHP reﬂect the unfolded nature of this
peptide.
In contrast, the consistency between theoretical and
apparent molecular weights for R30 illustrates the folded
nature of R30. Importantly, PrDOS-based analysis of full
length 4.1R135 predicted the 30kDa domain to be the only
region in the whole protein to adopt an ordered (folded)
structure. The crystal structure of 4.1R 30kDa domain is
reminiscent of the shape of a cloverleaf or of a propeller,
with three clearly distinct lobes (PDB: 1GG3) [25]. First,
the N-lobe, corresponding to the ﬁrst 78 amino acids
and which includes the band 3 binding motif L37EEDY,
consists of 4 double-stranded β-strands. Second, the α-lobe,
corresponding to the following 90 amino acids and which
includes the GPC binding site, consists of 4 α-helices. Third,
the COOH-terminal lobe (C-lobe), which contains the p55
binding surface, is made of seven β-strands, and ends with
an α-helix (Figure 4). Although many membrane skeletal
proteins contain intrinsically disordered (unfolded) regions,
there are very few reports describing the function(s) of these
intrinsically disordered region [30–35]. Our ﬁndings will
contributenotonlytoabetterunderstandingofthestructure
of membrane skeletal proteins but also of the function of
intrinsically disordered proteins.
2.3. Expression of 4.1R135 and 4.1R80. In early stages of
erythroblasts (CD34+ cells), 4.1R135 is the only isoform
detected, 4.1R80 being completely absent. After the mid-
dle stage, which is reached after approximately 7 days
in culture, expression of 4.1R80 increases dramatically. In
mature erythrocytes, 4.1R80 predominates, 4.1R135 being
hardly seen by immunocytochemical methods [29]. The
complex mechanistic of 4.1R135-4.1R80 gene switching has
been recently described by Parra et al. [36, 37].
2.4. Binding Proﬁles of 4.1R135 and 4.1R80 to Membrane
Proteins and CaM Diﬀer. Previous studies have shown that,
while 4.1R80 binds to both band 3 and GPC in native inside-
out vesicles (IOVs), it binds only to GPC in trypsinized IOVs
[32]. Scatchard analysis indicates an apparent dissociation
constant at equilibrium, K , of 76nM for 4.1R80 binding to
trypsinized IOVs (i.e., to GPC). In contrast, K  for 4.1R80
bindingtonativeIOVs(i.e.,tobothGPCandband3)reaches
340nM. A similar analysis for 4.1R135 revealed that 4.1R135
binding to trypsinized IOVs (i.e., to GPC) is markedly
weaker (K  of ∼2μM) than that of 4.1R80. In contrast, K 
for 4.1R135 binding to native IOVs is 230nM, similar to thatInternational Journal of Cell Biology 5
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Figure 4: Primary structure of 4.1R isoforms and map of known binding partners for 4.1R. Translation of the prototypical red blood
cell 80kDa 4.1R isoform (4.1R80) is initiated at AUG-2, which is located in exon 4. Translation of the 135kDa 4.1R isoform (4.1R135), an
isoform expressed in early erythroblasts and other nucleated cells, is initiated at AUG-1, which is located in exon 2  (ID: P11171). The
30kDa membrane-binding domain is the so-called “FERM” domain. Disorder prediction for each domain has been established through the
use of the PrDOS software package. An updated list of the binding partners identiﬁed for each domain of 4.1R is displayed. CPAP refers
to a “centrosomal protein 4.1R-associated protein”r e p o r t e db yH u n ge ta l .[ 24]. A 3D representation of the 30kDa FERM domain of 4.1R,
visualized with the MolFeat Ver. 4.6 software, is displayed (PDB accession no. 1GG3). The 30kDa domain consists of three lobes (N-, α-,
and C-lobe) and adopts a three-leaf clover shape [25].
pep2: S76RGLSRLFSSFLKRPKS
S394(185)
pep11:A473(264)KKLWKVCVEHHTFFRL
HP
Figure 5: Mapping of the CaM-binding sites in 4.1R. 4.1R135 has three CaM-binding sites: pep2 in the HP region, S185 being the key residue
for Ca2+-sensitive site, and Ca2+-independent sequence; pep9 and pep11 in the FERM domain. Numbers in parenthesis indicate amino acid
numbering for 4.1R80 (AUG2 form in Figure 4).6 International Journal of Cell Biology
4.1R135
(erythroblasts)
4.1R80
(erythrocytes)
K(D) = 10−8M
10−6M 10−6M No binding
Increasing
[Ca2+]i
Band 3 Band 3
p55 p55 CaM
HP
30kDa
HP
30kDa
HP
30kDa
HP
30kDa
K(D) = 10−7M 10−6M1 0 −6M 10−7M
Band 3 Band 3
p55 p55
30kDa 30kDa 30kDa 30kDa
GPC GPC
GPC GPC
Figure 6: Model proposed for Ca2+/CaM-dependent regulation of 4.1R binding to membrane proteins. Erythroblast intracellular Ca2+
concentration is normally maintained at less than 0.1μM( 1 0 −7 M) [39, 40]( upper panel). At higher Ca2+ concentrations, CaM binds to the
HP region. This results in a conformational and/or electric surface change which alters 4.1R binding sites, 4.1R135 interacting consequently
withloweraﬃnity with its binding partner band 3 and no longer interacting with GPC, and p55. This model implies a Ca2+/CaM-dependent
regulation of protein 4.1R binding to transmembrane proteins. Erythrocyte intracellular Ca2+ concentration is normally maintained at less
than 1.0μM( 1 0 −6 M) (lower panel). At this Ca2+ concentration, CaM is bound predominantly to the Ca2+-independent site located in
peptide 11 of the 30kDa domain (see [12, 38]). At higher Ca2+ concentrations, CaM-binding aﬃnity for the Ca2+-dependent site, located
in peptide 9 of the 30kDa domain, increases. This results in a conformational and/or electric surface change which alters 4.1R binding
sites, 4.1R interacting consequently with lower aﬃnity with its binding partners p55, GPC, and spectrin/actin. This model implies that CaM
regulates protein 4.1R binding to transmembrane proteins through Ca2+-independent and Ca2+-dependent binding sites.
observed for 4.1R80. These ﬁndings imply that the presence
or absence of HP in 4.1R isoforms modulates their binding
aﬃnity for GPC but not for band 3 [29].
In order to obtain independent conﬁrmation of the
binding aﬃnities of 4.1R135 to band 3cyt and GPCcyt, we
usedtheIAsyssystembasedontheresonantmirrordetection
method [29]. In agreement with the binding data using
IOVs described above, there was a dramatic diﬀerence in
the binding aﬃnity of 4.1R135 to band 3cyt and GPCcyt,
the binding aﬃnity being much higher for band 3cyt (23
± 2nM) than for GPCcyt (1327 ± 103nM). In marked
contrast, K(D) values for binding of 4.1R80 to both band 3cyt
and GPCcyt were very similar, in the submicromolar range.
This conﬁrmed an important role for HP in regulating 4.1R
aﬃnities for its two major transmembrane binding partners.
In contrast to the marked diﬀerences in the binding aﬃnities
of 4.1R135 and 4.1R80 to band 3cyt and GPCcyt, the two
isoforms bound to p55 with very similar aﬃnities, in the
submicromolar range.
As expected from the data obtained with 4.1R80 and
4.1R135 isoforms, the addition of RHP to R30 (RHP-R30)
results in a profound change in the ability of R30 to bind
to band 3cyt and GPCcyt. Thus, the binding aﬃnity of
RHP-R30 for band 3cyt is 35-fold higher than for GPCcyt.
Together, these ﬁndings highlight an important role for RHP
inmodulatingtheinteractionofR30withitstwomembrane-
binding partners.
2.5. Diﬀerences in CaM Binding to 4.1R Isoforms. We have
previously documented that 4.1R80 binds to CaM with a
K(D) in the submicromolar range, both in the presence
and absence of Ca2+ implying that this interaction is Ca2+-
independent [38]. We have also examined the nature of
the interaction between 4.1R135 and CaM. Kinetic analysis
of 4.1R135 interaction with CaM using the IAsys system
identiﬁed a very strong interaction with a K(D) of 51 ± 5nM
in the presence of Ca2+. In the absence of Ca2+, the binding
aﬃnity decreased by over 100-fold. Thus, in contrast to
4.1R80, the interaction of 4.1R135 with CaM is strongly Ca2+
dependent. Probing of the HP region alone conﬁrms a Ca2+-
dependent interaction with CaM, implying that this region
harbors the CaM-binding site [27, 28]. Our observations are
in accordance with Leclerc and Vetter’s study that identiﬁes
the S76RGLSRLFSSFLKRPKS peptide as the Ca2+-dependentInternational Journal of Cell Biology 7
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Figure 7: Eﬀect of EGTA on the distribution of 4.1R135 in human erythroblasts (cultured for 7 days). Human erythroblasts were cultured in
the presence or absence of 1mM EGTA and immunostained with a rabbit antibody to RHP as previously described [29].
CaM binding sequence in RHP [27, 28]( Figure 5). The
stoichiometry of 4.1R135 binding to CaM in the presence of
Ca2+ is 1:1 as assessed by the quartz crystal microbalance
(QCM) method. These results indicate that Ca2+/CaM binds
to the HP region but not to the 30kDa domain [29].
2.6.Regulationof4.1R135 InteractionswithMembraneProteins
by Ca2+/CaM. The binding aﬃnity of 4.1R135 for band 3cyt
is decreased by almost 2 orders of magnitude by Ca2+/CaM.
Moreover, Ca2+/CaM completely abolishes the ability of
4.1R135 to bind to either GPCcyt or p55. Either 5μMC a M
or 100μMC a 2+ alone has no aﬀect on binding aﬃnities.
4.1R135 binding to band 3cyt starts to decline at [Ca2+]i
greater than 10nM (pCa < 8) with a maximal inhibition
at 100μM( pCa > 4). Half maximal binding is observed
at a [Ca2+]i of 3.2μM( pCa = 5.5). In the case of 4.1R80,
Ca2+/CaM binding to the 30kDa domain reduces about
10 times the binding aﬃnity for band 3. Thus, we noted
signiﬁcant diﬀerences between 4.1R135 and 4.1R80 in the
Ca2+-dependence for the binding of these two isoforms to
CaM.IncontrasttotheCa2+-independentbindingofCaMto
4.1R80, CaM binding to 4.1R135 is strongly Ca2+ dependent.
This diﬀerence is once again directly attributable to the HP
region present in 4.1R135. Importantly, in contrast to band
3 and GPC that do not directly bind to the HP region,
this region by itself binds to CaM in a Ca2+-dependent
manner. Thus, it must be inferred that the CaM-binding site
in the HP region is the dominant binding site for CaM in
4.1R135 and that this site prevents the binding of CaM to
the Ca2+-independent binding site in 4.1R80. Furthermore,
our ﬁnding that CaM dramatically decreases the binding of
4.1R135 to band 3 in a Ca2+-dependent manner and abolishes
its binding to GPC and p55 has implications for the function
of this 4.1R isoform in early erythroblasts. Indeed, while low
levels of Ca2+ in early erythroblasts will lead to membrane
association through high-aﬃnity interaction with band 3,
increasing levels of Ca2+ during erythroid diﬀerentiation will
lead to the displacement of the protein from the membrane
and to a possible degradation and loss of this isoform from
erythroblasts. Our ﬁndings that, in early erythroblasts, a
fraction of 4.1R135 is actually associated with the membrane
lends support to this hypothesis [29]( Figure 6). Strikingly,
in human erythroblasts cultured for 7 days and treated
with 1mM EGTA, 4.1R135 is more clearly distributed at
or near the plasma membrane than in nontreated cells
(Figure 7). Precise quantitative measurements of Ca2+ levels
in erythroblasts at diﬀerent stages of maturation need to be
performed to validate further this hypothesis.
3.PART II:4.1R135 and 4.1G inErythroblasts
4.1R135 and 4.1G are simultaneously expressed in erythrob-
lasts and in nonerythroid cells, such as epithelial cells [42,
43].Thestructureofthe30kDa(FERM)domainof4.1Rand
4.1G is very similar. To date, there has not been any report
about functional diﬀerences between 4.1R135 and 4.1G. We
have shown for the ﬁrst time diﬀerences in binding proﬁles
of these two 4.1 proteins to membrane proteins.
3.1. Structural Similarity between 4.1R135 and 4.1G. The
primary amino acid sequence of the 30kDa domain of 4.1G
is 71% identical to that of 4.1R [42] (ID: O43491). 4.1G
is therefore predicted to bind to many of the previously
identiﬁed 4.1R binding partners. In contrast to the high8 International Journal of Cell Biology
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Figure 8: Primary structure of 4.1G. The primary structure of 4.1G resembles that of 4.1R135. In vitro binding assays show that the 30kDa
domain of 4.1G binds to previously characterized 4.1R binding partners. Modeling of 4.1G FERM domain 3D structure was performed in
silico [41]. Spectrin and actin binding sites in 4.1G C-terminal domain are not displayed.
conservation of the 30kDa domain, the amino acid sequence
identity of the HP region of 4.1G and 4.1R135 is quite low
(35%). We therefore hypothesized that the HP region of 4.1R
and 4.1G might regulate diﬀerently the binding properties of
their respective 30kDa domain.
Computer analysis of the 3D structure of the 30kDa
domain of 4.1G has demonstrated that its folded clover-like
structure is very similar to that of 4.1R [41]( Figure 8). This
observation validates the structural basis for 4.1G binding to
previously deﬁned 4.1R binding partners through its 30kDa
domain. As observed for the 30kDa domain of 4.1R, 4.1G
couldalsointeractwithCaMinaCa2+-independentmanner.
Using a combination of computational calculations
(aimed at calculating the disorder probability based on
PrDOS software analysis), SDS-PAGE analysis and size
exclusion chromatography, we established that, like the HP
regionof4.1R,theHPregionof4.1Gadoptsanunstructured
state [41]. As expected from their similar structure, R30
and G30 are both folded polypeptides, this 30kDa region
representing the only structured (folded) domain for both
proteins [41].
3.2. Expression of 4.1G and 4.1R135 in Erythroblasts. In
erythroblasts, both 4.1G and 4.1R are expressed whereas the
twoother4.1geneproducts,4.1Band4.1N,arenot(personal
communication, Narla Mohandas, New York Blood Center).
4.1G is expressed after 7–12 days of culture as a ∼70kDa iso-
form containing the HP region. This suggests the occurrence
of alternative splicing events targeting domains downstream
of the HP region (FERM domain, spectrin-actin binding
domain and/or C-terminal domain) in 4.1G.
3.3. Diﬀerences in Binding Proﬁles of 4.1R135 and 4.1G to
Membrane Proteins. 4.1G binds to IOVs prepared from
erythrocyte membranes. The apparent K  values for 4.1G
FERM domain (G30) and full length 4.1G binding to IOVs
are 169 ± 67nM and 207 ± 49nM, respectively, as assessed
by Scatchard plot analysis. These values are similar to
those obtained using resonant mirror detection [41]. These
ﬁndings demonstrate that 4.1G can bind to transmembrane
proteins of the erythrocyte membrane through its 30kDa
domain.
4.1G interacts in vitro with band 3cyt and GPCcyt
with K(D)s in the ∼200nM range. Importantly, the binding
aﬃnitiesof4.1Gforband3cytandGPCcytarediﬀerentfrom
those of 4.1R135 despite the presence of an HP region in both
proteins. Thus, 4.1G interacts with band 3cyt with a much
lower aﬃnity than 4.1R135, the reverse being observed for
GPCcyt. These diﬀerences result mainly from diﬀerences in
the association rate constant ka. In contrast, both 4.1G and
4.1R135 interact with p55 with similar aﬃnities [44].
Binding aﬃnities of full length 4.1G and of its 30kDa
domain (G30) for the membrane proteins described above
are very similar, suggesting that 4.1G interacts with its
binding partners primarily through G30, the headpiece GHP
having a negligible eﬀect on these interactions. This is in
marked contrast to the interactions of the 30kDa domain
of 4.1R (R30) which are signiﬁcantly aﬀected by RHP [29].International Journal of Cell Biology 9
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Figure 9: Model proposed for Ca2+/CaM-dependent regulation of 4.1G binding to membrane proteins. Erythroblast intracellular Ca2+
concentration is normally maintained at less than 0.1μM( 1 0 −7 M) as described in Figure 7 [39, 40]. 4.1G binds to band 3, GPC and p55
with a K(D) of 10−7 M. At higher Ca2+ concentrations, CaM binds to the HP region with a K(D) of 10−8 M. This results in a conformational
and/orelectricsurfacechangewhichalters4.1Gbindingsites,4.1GinteractingconsequentlywithloweraﬃnitywithitsbindingpartnersGPC
and no longer interacting with band 3 and p55. This model implies a Ca2+/CaM-dependent regulation of 4.1G binding to transmembrane
proteins.
Interestingly, recombinant chimera proteins consisting of
either RHP and G30 (RHP-G30) or GHP and R30 (GHP-
R30) showed similar binding aﬃnities as G30 and R30. This
implied signiﬁcant diﬀerences in the structure and function
of RHP and GHP. It should be noted that neither GHP nor
RHP binds to any of these membrane proteins.
We showed an important role for the HP region in
regulating 4.1R135 30kDa domain binding to membrane
proteins.Thus,theHPregionimprovesaccessibilityoftheN-
lobe to band 3, but impairs accessibility of the α-lobe to GPC
whereas it does not have a signiﬁcant eﬀect on the C-lobe
[29]. 4.1G HP does not appear to modulate the accessibility
of the three lobes in G30 to their respective binding partners,
the binding proﬁle of 4.1G being similar to that of G30.
We demonstrated that 4.1G binds to various previously
characterized 4.1R binding partners, including transmem-
brane proteins band 3, GPC, and p55, through its 30kDa
domain. The HP domain does not aﬀect these interactions.
However, Ca2+-dependent CaM binding to the HP region
has a profound eﬀect on the interaction of 4.1G with its
binding partners. The documented binding proﬁles for 4.1G
are markedly diﬀerent from those previously reported for
4.1R135 [29]. Since the primary structure of the 30kDa
domain of 4.1G and 4.1R is highly conserved (71% sequence
similarity), the diﬀerences in binding proﬁles are likely to
arise primarily from the nonconserved HP region.
3.4. Similarities and Diﬀerences of CaM Binding to HP and
30kDa Domains of 4.1R and 4.1G. Both full length 4.1G and
GHP bind to a CaM Sepharose 4B column in the presence of
Ca2+ and can be eluted with 5mM EGTA. The K(D) for CaM
binding to 4.1G and GHP increases dramatically following
chelation of Ca2+ with EGTA. These ﬁndings establish that
CaM binds to 4.1G HP region in a Ca2+-dependent manner.
T h e s ed a t ar e c a p i t u l a t ep r e vi o u so b s e rv a t i o n sm a d ef o rC a M
binding to RHP and 4.1R135 [29]. The binding aﬃnity of
4.1G to Ca2+/CaM is ∼10nM, and the stoichiometry is ∼1:1
[41]. This observation strongly supports the importance of
the HP region in mediating Ca2+-dependent CaM binding to
4.1G.
However, although CaM binds to the HP region of
4.1G in a Ca2+-dependent manner, it does not bind
to 4.1G 30kDa domain, as previously documented for
4.1R80 [38]. The HP region of 4.1G contains a sequence10 International Journal of Cell Biology
S71RGISRFIPPWLKKQKS that is 76% identical (13/17
residues) to the CaM-binding site in the HP region of 4.1R
(S76RGLSRLFSSFLKRPKS) [27, 28]. Although the Ca2+-
independent CaM-binding sequence previously identiﬁed in
the 30kDa domain of 4.1R80 is conserved in 4.1G [41],
our results indicate that CaM binds to the HP region
but not to the 30kDa domain of 4.1G. It should be
emphasized that although the HP by itself does not aﬀect the
binding of the 30kDa domain of 4.1G to various membrane
proteins, Ca2+/CaM binding to the HP markedly inhibits the
ability of the 30kDa domain of 4.1G to interact with its
various binding partners. These ﬁndings have enabled us to
document similarities and diﬀerences in the structural and
functional properties of 4.1G and 4.1R135.
3.5. Ca2+/CaM-Dependent Regulation of 4.1G Binding to
Membrane Proteins. We have shown that Ca2+/CaM binding
to the headpiece of 4.1G results in a complete inhibition
of 4.1G binding to band 3cyt and p55 and in a signiﬁcant
increase in the K(D) for 4.1G binding to GPCcyt. In light
of the fact that CaM binds to the 30kDa domain on 4.1R80
in the absence of Ca2+ and that CaM binding decreases the
K(D) of R30 for its binding partners in a Ca2+-dependent
manner [17, 44], we examined the eﬀect of CaM binding to
G30 on its binding properties to membrane proteins using a
RHP-G30chimeraprotein.BindingaﬃnitiesofRHP-G30for
band 3cyt, GPCcyt, p55, and CD44cyt were measured in the
presence or absence of Ca2+ and CaM. The K(D)s obtained
for each binding partner in the absence of CaM were
similar to those obtained with full-length 4.1G. In contrast,
binding assays performed with RHP-G30 preincubated with
Ca2+/CaM showed a major decrease in binding aﬃnity (7–10
fold in K(D)) of RHP-G30 for band 3cyt, GPCcyt, and p55.
These results indicate that although CaM can bind to G30
independently of Ca2+, G30 interactions with membrane
proteins can be regulated by CaM in a Ca2+-dependent
manner. These results also indicate that the regulation of
30kDa domain binding properties by unfolded HP domain
has unique features in the case of 4.1R135 and 4.1G.
The Ca2+ concentration dependence of the CaM-
modulated interaction of 4.1G with band 3cyt and GPCcyt
has been demonstrated [38, 44]. The half maximal binding
of 4.1R135 and 4.1G to band 3cyt and GPCcyt occurs at Ca2+
concentrations in the submicromolar range [39, 40], sup-
porting the potential biological relevance of our biochemical
ﬁndings [29]. Ca2+/CaM-dependent modulations of 4.1R135
and 4.1G binding to membrane proteins may be triggered
upon signal transduction during erythroid development.
Indeed, it has been documented that, at early stages of
erythropoiesis, intracellular calcium levels increased from a
basal level of 55 ± 5nM to 259 ± 49nM following binding
of erythropoietin to its receptor [39]. Such an increase in
intracellular calcium levels would be suﬃcient to modulate
the interaction of 4.1R135 and 4.1G with its binding partners
in erythroid cells. Our ﬁndings further suggest that 4.1G
oﬀers a unique opportunity to explore divergence of protein
structure and function during evolution and development.
In erythroblasts, we showed that, consistent with earlier
reports [42, 43], 4.1G and 4.1R135 are both expressed during
terminal erythroid diﬀerentiation and that both proteins
can interact with common transmembrane proteins, such
as band 3, GPC, and p55. Diﬀerent binding aﬃnities and
Ca2+/CaM-dependent modulation of interaction with band
3 and GPC suggest that these 4.1 proteins may play speciﬁc
roles in membrane biogenesis during terminal erythroid
diﬀerentiation (Figure 9).
Thus, the unstructured HP domains of 4.1R and 4.1G
seem to play a unique role in regulating the membrane-
binding properties of those proteins. Understanding the
structural basis for diﬀerences and similarities in 4.1 binding
properties will help us unveil novel biological functions for
various 4.1 gene products. To that end, we are currently car-
rying out a structural analysis of the HP-Ca2+/CaM complex
using NMR and small-angle X-ray scattering (SAXS). These
biophysical analyses should help us further understand the
structural basis for the regulatory role of the unstructured
HP domain.
4. Conclusion
During erythropoiesis, the HP domain acts as a regulator
of 4.1R and 4.1G interaction with the plasma membrane.
We hypothesize that these regulatory properties are in
part the result of the unstructured conformation of the
HP region. We also show that these regulatory properties
depend on intracellular calcium concentrations, with these
concentrations varying during erythropoiesis. Thus, the
function of the HP domain may evolve depending on the
structure of the 4.1 protein isoforms expressed at each stage
of erythropoiesis.
5. FutureStudieson 4.1R135 and4.1G
This paper focuses on the structure and function of
the N-terminal intrinsically disordered region (HP) and
membrane-binding FERM domain of 4.1R135 and 4.1G and
on the role of Ca2+ in regulating binding to membrane
proteins through CaM. Our ﬁndings are based on in vitro
binding assays. Direct evidence for these interactions and
their regulations in living cells remains to be established.
AlthoughitisknownthattheRHPcontainsphosphorylation
sites [28, 45], the relationship between Ca2+/CaM regulation
and phosphorylation remains to be investigated. 4.1G binds
to spectrin/actin [46, 47] and receptors through its C-
terminal region [48, 49]. Does Ca2+/CaM binding to HP
also regulate these interactions? Answering such mechanistic
questions will help us deﬁne the biological signiﬁcances of
4.1R135 and 4.1G in the late stage of erythropoiesis.
Appendix
Tables 1 and 2 summarize 4.1R135 and 4.1G binding kinetic
parameterstothecytoplasmictailsofband3andGPCandto
CaM in the presence or the absence of Ca2+. Although both
4.1R135 and 4.1G bind to Ca2+/CaM in the ∼10−8 M K(D)
range, the K(D) of 4.1R135 binding to CaM is 5 times higher
than 4.1G in the absence of Ca2+. These results suggest thatInternational Journal of Cell Biology 11
Table 1: 4.1R135 and 4.1G binding to membrane proteins.
Analyte Ligand Ka (M−1 s−1) Kd (s−1) KD (nM)
4.1R135 band 3cyt 3.1 ± 0.2 × 105 7.1 ± 0.2 × 10−3 23 ± 2
GPCcyt 8.0 ± 0.2 × 103 1.1 ± 0.1 × 10−2 1327 ± 103
4.1G band 3cyt 8.0 ± 0.1 × 104 1.4 ± 0.1 × 10−2 185 ± 23
GPCcyt 5.6 ± 0.1 × 104 8.1 ± 0.2 × 10−3 144 ± 5
Table 2: 4.1R135 and 4.1G binding to CaM.
Analyte Ligand Condition Ka (M−1 s−1) Kd (s−1) KD (nM)
4.1R135 CaM EGTA 1.4 ± 0.2 × 103 1.6 ± 0.1×10−2 11659 ± 2890
Ca2+ 2.0 ± 0.1 × 105 1.5 ± 0.1×10−2 78 ± 10
4.1G CaM EGTA 3.7 ± 0.2 × 103 8.3 ± 0.1 ×10−3 2245 ± 41
Ca2+ 9.4 ± 0.2 × 104 5.1 ± 0.2 × 10−3 54 ± 3
the binding proﬁles of 4.1R and 4.1G may diﬀer in respect to
CaM.
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RHP-R30: Fusion protein of RHP and R30
RHP-G30: Chimera protein of RHP and G30.
Acknowledgment
This work was supported in part by Grant-in-Aid for
Scientiﬁc Research from the Ministry of Education Culture,
Sport, Science and Technology of Japan 15570123 for W.
Nunomura.
References
[1] V. Bennett and A. J. Baines, “Spectrin and ankyrin-based
pathways: metazoan inventions for integrating cells into
tissues,” Physiological Reviews, vol. 81, no. 3, pp. 1353–1392,
2001.
[ 2 ]N .J .H e m m i n g ,D .J .A n s t e e ,W .J .M a w b y ,M .E .R e i d ,a n d
M. J. A. Tanner, “Localization of the protein 4.1-binding site
on human erythrocyte glycophorins C and D,” Biochemical
Journal, vol. 299, no. 1, pp. 191–196, 1994.
[3] N. J. Hemming, D. J. Anstee, M. A. Staricoﬀ,M .J .A .
Tanner, and N. Mohandas, “Identiﬁcation of the membrane
attachment sites for protein 4.1 in the human erythrocyte,”
Journal of Biological Chemistry, vol. 270, no. 10, pp. 5360–
5366, 1995.
[4] S. M. Marfatia, R. A. Lue, D. Branton, and A. H. Chishti,
“Identiﬁcation of the protein 4.1 binding interface on gly-
cophorin C and p55, a homologue of the Drosophila discs-
large tumor suppressor protein,” Journal of Biological Chem-
istry, vol. 270, no. 2, pp. 715–719, 1995.
[5] M. Yageta, M. Kuramochi, M. Masuda et al., “Direct associ-
ation of TSLC1 and DAL-1, two distinct tumor suppressor
proteins in lung cancer,” Cancer Research, vol. 62, no. 18, pp.
5129–5133, 2002.
[6] J. A. Girault, G. Labesse, J. P. Mornon, and I. Callebaut, “Janus
kinases and focal adhesion kinases play in the 4.1 band: a
superfamily of band 4.1 domains important for cell structure
and signal transduction,” Molecular Medicine, vol. 4, no. 12,
pp. 751–769, 1998.
[7] H. Kusunoki and T. Kohno, “Structural insight into the
interaction between the p55 PDZ domain and glycophorin
C,”BiochemicalandBiophysicalResearchCommunications,vol.
359, no. 4, pp. 972–978, 2007.
[8] S. D. Dimitratos, D. F. Woods, D. G. Stathakis, and P. J. Bryant,
“Signaling pathways are focused at specialized regions of the
plasma membrane by scaﬀolding proteins of the MAGUK
family,” BioEssays, vol. 21, no. 11, pp. 912–921, 1999.
[9] B. J. Quinn, E. J. Welch, A. C. Kim et al., “Erythrocyte scaf-
folding protein p55/MPP1 functions as an essential regulator
of neutrophil polarity,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 106, no. 47, pp.
19842–19847, 2009.
[10] P. Mburu, Y. Kikkawa, S. Townsend, R. Romero, H. Yonekawa,
and S. D. M. Brown, “Whirlin complexes with p55 at the
stereocilia tip during hair cell development,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 103, no. 29, pp. 10973–10978, 2006.
[11] P.Mburu,M.R.Romero,H.Hiltonetal.,“Gelsolinplaysarole
in the actin polymerization complex of hair cell stereocilia,”
PLoS ONE, vol. 5, no. 7, article e11627, 2010.12 International Journal of Cell Biology
[12] W. Nunomura and Y. Takakuwa, “Regulation of protein
4.1R interactions with membrane proteins by Ca2+ and
calmodulin,” Frontiers in Bioscience, vol. 11, no. 2, pp. 1522–
1539, 2006.
[13] P. Michaely and V. Bennett, “The ANK repeats of erythrocyte
ankyrinformtwodistinctbutcooperativebindingsitesforthe
erythrocyte anion exchanger,” Journal of Biological Chemistry,
vol. 270, no. 37, pp. 22050–22057, 1995.
[14] T. Jons and D. Drenckhahn, “Identiﬁcation of the binding
interface involved in linkage of cytoskeletal protein 4.1 to the
erythrocyte anion exchanger,” EMBO Journal,v o l .1 1 ,n o .8 ,
pp. 2863–2867, 1992.
[15] D. Zhang, A. Kiyatkin, J. T. Bolin, and P. S. Low, “Crys-
tallographic structure and functional interpretation of the
cytoplasmic domain of erythrocyte membrane band 3,” Blood,
vol. 96, no. 9, pp. 2925–2933, 2000.
[16] X. L. An, Y. Takakuwa, W. Nunomura, S. Manno, and N.
Mohandas, “Modulation of band 3-ankyrin interaction by
protein 4.1: functional implications in regulation of erythro-
cyte membrane mechanical properties,” Journal of Biological
Chemistry, vol. 271, no. 52, pp. 33187–33191, 1996.
[17] W. Nunomura, Y. Takakuwa, R. Tokimitsu, S. W. Krauss,
M. Kawashima, and N. Mohandas, “Regulation of CD44-
protein 4.1 interaction by Ca2+ and calmodulin. Implications
for modulation of CD44-ankyrin interaction,” Journal of
Biological Chemistry, vol. 272, no. 48, pp. 30322–30328, 1997.
[18] W. Nunomura, Y. Takakuwa, G. N. Cherr, and K. Murata,
“Characterization of protein 4.1R in erythrocytes of zebraﬁsh
(Daniorerio): unique binding properties with transmembrane
proteins and calmodulin,” Comparative Biochemistry and
Physiology B, vol. 148, pp. 124–138, 2007.
[19] K. Murata, W. Nunomura, Y. Takakuwa, and G. N. Cherr,
“Two diﬀerent unique cardiac isoforms of protein 4.1R in
zebraﬁsh,Daniorerio,andinsightsintotheircardiacfunctions
asrelatedtotheiruniquestructures,”DevelopmentGrowthand
Diﬀerentiation, vol. 52, no. 7, pp. 591–602, 2010.
[20] M. Salomao, X. Zhang, Y. Yang et al., “Protein 4.1R-dependent
multiprotein complex: new insights into the structural orga-
nization of the red blood cell membrane,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 105, no. 23, pp. 8026–8031, 2008.
[21] E. Shaﬁzadeh, B. H. Paw, H. Foott et al., “Characterization
of zebraﬁsh merlot/chablis as non-mammalian vertebrate
models for severe congenital anemia due to protein 4.1
deﬁciency,” Development, vol. 129, no. 18, pp. 4359–4370,
2002.
[22] Y. Takakuwa, “Protein 4.1, a multifunctional protein of the
erythrocyte membrane skeleton: structure and functions in
erythrocytes and nonerythroid cells,” International Journal of
Hematology, vol. 72, no. 3, pp. 298–309, 2000.
[23] W. Diakowski, M. Grzybek, and A. F. Sikorski, “Protein 4.1,
a component of the erythrocyte membrane skeleton and its
related homologue proteins forming the protein 4.1/FERM
superfamily,” Folia Histochemica et Cytobiologica, vol. 44, no.
4, pp. 231–248, 2006.
[ 2 4 ]L .Y .H u n g ,C .J .C .T a n g ,a n dT .K .T a n g ,“ P r o t e i n4 . 1R - 1 3 5
interacts with a novel centrosomal protein (CPAP) which is
associatedwiththeγ-tubulincomplex,”MolecularandCellular
Biology, vol. 20, no. 20, pp. 7813–7825, 2000.
[25] B. G. Han, W. Nunomura, Y. Takakuwa, N. Mohandas, and
B. K. Jap, “Protein 4.1R core domain structure and insights
intoregulationofcytoskeletal organization,” Nature Structural
Biology, vol. 7, no. 10, pp. 871–875, 2000.
[26] T. Ishida and K. Kinoshita, “PrDOS: prediction of disordered
protein regions from amino acid sequence,” Nucleic Acids
Research, vol. 35, pp. W460–W464, 2007.
[27] G. M. Kelly, B. D. Zelus, and R. T. Moon, “Identiﬁcation of a
calcium-dependent calmodulin-binding domain in Xenopus
membrane skeleton protein 4.1,” Journal of Biological Chem-
istry, vol. 266, no. 19, pp. 12469–12473, 1991.
[28] E. Leclerc and S. Vetter, “Characterization of a calcium-
dependent calmodulin-binding domain in the 135-kD human
protein 4.1 isoform,” European Journal of Biochemistry, vol.
258, no. 2, pp. 567–571, 1998.
[29] W. Nunomura, M. Parra, M. Hebiguchi, K. I. Sawada,
N. Mohandas, and Y. Takakuwa, “Marked diﬀerence in
membrane-protein-binding properties of the two isoforms of
protein 4.1R expressed at early and late stages of erythroid
diﬀerentiation,” Biochemical Journal, vol. 417, no. 1, pp. 141–
148, 2009.
[30] D. Eliezer, “Biophysical characterization of intrinsically disor-
dered proteins,” Current Opinion in Structural Biology, vol. 19,
no. 1, pp. 23–30, 2009.
[31] L. M. Espinoza-Fonseca, “Reconciling binding mechanisms of
intrinsically disordered proteins,” Biochemical and Biophysical
Research Communications, vol. 382, no. 3, pp. 479–482, 2009.
[32] A.K.Dunker,M.S.Cortese,P.Romero,L.M.Iakoucheva,and
V. N. Uversky, “Flexible nets: the roles of intrinsic disorder in
protein interaction networks,” FEBS Journal, vol. 272, no. 20,
pp. 5129–5148, 2005.
[33] Y. Minezaki, K. Homma, and K. Nishikawa, “Intrinsically
disordered regions of human plasma membrane proteins
preferentially occur in the cytoplasmic segment,” Journal of
Molecular Biology, vol. 368, no. 3, pp. 902–913, 2007.
[34] A. B. Sigalov, “Membrane binding of intrinsically disordered
proteins: critical importance of an appropriate membrane
model,” Self/Nonself—Immune Recognition and Signaling, vol.
1, no. 2, pp. 129–132, 2010.
[ 3 5 ]A .N ø r h o l m ,R .H e n d u s - A l t e n b u r g e r ,G .B j e r r e ,M .K j a e r -
gaard, S. F. Pedersen, and B. B. Kragelund, “The intracellular
distal tail of the Na+/H+ exchanger NHE1 is intrinsically
disordered: implications for NHE1 traﬃcking,” Biochemistry,
vol. 50, pp. 3469–3480, 2011.
[36] M.K.Parra,S.Gee,N.Mohandas,andJ.G.Conboy,“Eﬃcient
in vivo manipulation of alternative pre-mRNA splicing events
usingantisensemorpholinosinmice,”TheJournalofBiological
Chemistry, vol. 286, pp. 6033–6039, 2011.
[37] M. K. Parra, J. S. Tan, N. Mohandas, and J. G. Conboy,
“Intrasplicing coordinates alternative ﬁrst exons with alterna-
tive splicing in the protein 4.1R gene,” EMBO Journal, vol. 27,
no. 1, pp. 122–131, 2008.
[38] W. Nunomura, Y. Takakuwa, M. Parra, J. G. Conboy, and N.
Mohandas, “Ca2+-dependent and Ca2+-independent calmod-
ulin binding sites in erythrocyte protein 4.1. Implications for
regulation of protein 4.1 interactions with transmembrane
proteins,” Journal of Biological Chemistry, vol. 275, no. 9, pp.
6360–6367, 2000.
[ 3 9 ]R .V .Y e l a m a r t y ,B .A .M i l l e r ,R .C .S c a d u t oJ r . ,F .T .S .
Yu, D. L. Tillotson, and J. Y. Cheung, “Three-dimensional
intracellular gradients in single human brust-forming units-
erythroid-derived erythroblasts induced by erythropoietin,”
The Journal of Clinical Investigation, vol. 85, pp. 1799–1809,
1990.
[ 4 0 ]B .A .M i l l e r ,R .C .S c a d u t oJ r . ,D .L .T i l l o t s o n ,J .B o t t i ,a n dJ .
Y. Cheung, “Erythropoietin stimulates a rise in intracellular
free calcium concentartion in single early human erythroidInternational Journal of Cell Biology 13
precursors,” The Journal of Clinical Investigation, vol. 825, pp.
309–315, 1988.
[41] W. Nunomura, K. Kinoshita, M. Parra et al., “Similarities
and diﬀerences in the structure and function of 4.1G and
4.1R135, two protein 4.1 paralogues expressed in erythroid
cells,” Biochemical Journal, vol. 432, no. 2, pp. 407–416, 2010.
[42] M. Parra, P. Gascard, L. D. Walensky, S. H. Snyder, N.
Mohandas, and J. G. Conboy, “Cloning and characterization
of 4.1G (EPB41l2), a new member of the skeletal protein 4.1
(EPB41) gene family,” Genomics, vol. 49, no. 2, pp. 298–306,
1998.
[43] P. Gascard, G. Lee, L. Coulombel et al., “Characterization of
multiple isoforms of protein 4.1R expressed during erythroid
terminaldiﬀerentiation,”Blood,vol.92,no.11,pp.4404–4414,
1998.
[44] W. Nunomura, Y. Takakuwa, M. Parra, J. Conboy, and N.
Mohandas,“Regulationofprotein4.1R,p55,andGlycophorin
C ternary complex in human erythrocyte membrane,” Journal
of Biological Chemistry, vol. 275, no. 32, pp. 24540–24546,
2000.
[45] S. C. Huang, E. S. Liu, S. H. Chan et al., “Mitotic regulation
of protein 4.1R involves phosphorylation by cdc2 kinase,”
Molecular Biology of the Cell, vol. 16, no. 1, pp. 117–127, 2005.
[46] A. Kontrogianni-Konstantopoulos, C. S. Frye, E. J. Benz Jr.,
and S. C. Huang, “The prototypical 4.1R-10-kDa domain
and the 4.1G-10-kDa paralog mediate fodrin-actin complex
formation,” Journal of Biological Chemistry, vol. 276, no. 23,
pp. 20679–20687, 2001.
[47] J. A. Gimm, X. An, W. Nunomura, and N. Mohandas, “Func-
tional characterization of spectrin-actin-binding domains in
4.1 family of proteins,” Biochemistry, vol. 41, no. 23, pp. 7275–
7282, 2002.
[ 4 8 ]D .L u ,H .Y a n ,T .O t h m a n ,C .P .T u r n e r ,T .W o o l f ,a n dS .
A. Rivkees, “Cytoskeletal protein 4.1G binds to the third
intracellular loop of the A1 adenosine receptor and inhibits
receptor action,” Biochemical Journal, vol. 377, no. 1, pp. 51–
59, 2004.
[49] M. Saito, M. Sugai, Y. Katsushima, T. Yanagisawa, J. Sukegawa,
and N. Nakahata, “Increase in cell-surface localization of
parathyroid hormone receptor by cytoskeletal protein 4.1G,”
Biochemical Journal, vol. 392, no. 1, pp. 75–81, 2005.